NOVELLO E., MION M.M., ZANINOTTO M., PLEBANI M. Department of Laboratory Medicine, University-Hospital, Padova (Italy). AQT90 FLEX is a fully automatic.

Slides:



Advertisements
Similar presentations
CAP/POCT 2003 Carol Riley-Hunte, RRT Senior Education Specialist Bayer HealthCare.
Advertisements

P OINT OF CARE TESTING Lecture 6. D EFINITION Medical testing at or near the site of patient care. It is a mode of analysis which is performed at the.
Independent Project HCAI 5221 Evaluation of Point of Care Bedside Glucose Monitors for Use in a Specialty & Transplant Hospital Mary A. Weidner, BS, MT(ASCP)
AACB NSW/ACT QC Subcommittee TnT hs Survey Results Methods Results Introduction Persephone Giannopoulos¹ and representatives of the AACB NSW/ACT QC Subcommittee.
Increasing Demand for Reduced Test Turn Around Time (TAT) and Specimen Quality Emergency Department “I want SPEED” “I want specimen QUALITY & PURITY”
Early assessment of myocardial injury by joint measurement of TnT-hs and Copeptin (1) J. Teixeira, (2) P. Wotquenne, (2) V. D’Orio, (3) D. Gruson, (1)
0.1 pg/mL: Mean = 3.87 SD = %CV = 6.4% Mean LoD = 17 fg/mL Curve 1, LoD = pg/mL Curve 2, LoD = pg/mL Curve 3, LoD = pg/mL.
Comparative Performance of Dual 3rd Generation Immunoassays as a Potential Laboratory-Based HIV-1/2 Testing Strategy. B. Bennett, S. Fordan, O. David,
Procalcitonin Over the past two decades, the body of literature on the clinical usefulness of procalcitonin (PCT) in adults has grown rapidly. Although.
Deidra Huckabee MSN, RN, CCRN. Research Question Medical ICU staff inquired about the accuracy of utilizing the bedside Point of Care Testing (POCT) analyzer.
High Sensitivity Troponin
PHARM 462 PART / /31 Good Manufacturing Practices (GMP) VALIDATION of ANALYTICAL TEST METHODS.
L MACKAY, N CRINIS, Q LAM, R SCOTT
Quality Improvement in the Emergency Department Creating the culture so it’s second nature Jonathan A. Edlow, MD Associate Professor of Medicine Harvard.
OnSite Troponin I Rapid Test
Overly concerning and falsely reassuring?? FRAMINGHAM RISK FACTORS IN THE ED.
Journal Club Electronic Medical Record–Based Performance Improvement Project to Document and Reduce Excessive Cardiac Troponin Testing S.A. Love, Z.J.
HIV Testing CDC power point edited by M. Myers
BOHB APCCB LABORATORY USE OF THE ABBOTT MEDISENSE METER FOR BETA-HYDROXYBUTYRATE MEASUREMENT. GRD Jones, A Screnci, P Graham Chemical Pathology,
OnSite Troponin I Rapid Test. Cardiac markers are biomarkers measured to evaluate heart function.biomarkers They are often discussed in the context of.
Introduction to the Principles of Laboratory Medicine Photos by Theresa Kristopaitis, MD.
Journal Club MicroRNA In Vitro Diagnostics by Use of Immunoassay Analyzers A. Kappel, C. Backes, Y. Huang, S. Zafari, P. Leidinger, B. Meder, H. Schwarz,
Validation of Analytical Method
Method Selection and Evaluation Method Selection and Evaluation D. Kefaya EL- Sayed Mohamed Prof. Of Clinical Pathology (Clinical Chemistry), Mansoura.
1 Chapter 5 Unit 4 Presentation ICD-9-CM Hospital Inpatient, Outpatient, and Physician Office Coding Shatondra Surulere, MBA, RHIA, CCS.
The Heart of the Matter A Journey through the system of care.
© Copyright 2009 by the American Association for Clinical Chemistry Plasma Myeloperoxidase Predicts Incident Cardiovascular Risks in Stable Patients Undergoing.
Performance Characteristics of the FARRZYME™ High Avidity Anti-dsDNA IgG Antibody ELISA Brenda B. Suh-Lailam 1, Tyson R. Chiaro 1, K. Wayne Davis 1, Andrew.
CORPORATE INNOVATION AS AN ENGINE FOR CHANGE: Molecular Diagnostics David Okrongly, Ph.D. SVP Molecular Diagnostics Siemens Healthcare.
Quality Control Lecture 5
Summary This study has been able to answer: Research Problem: – The ability of nurses to perform specific tasks affected by the inadequacy of workforce.
Biochemical Markers for Diagnosis of Myocardial Infarction Cardiovascular Block Medical Biochemistry Course Dr. Reem M. Sallam, MD, PhD.
Evaluation of the Presage™ ST2 ELISA Jun Lu 1, David G. Grenache 1,2 1 ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT 2 Department.
Association of C-Reactive Protein and Acute Myocardial Infarction in HIV-Infected Patients Virginia A. Triant, MD, MPH, James B. Meigs, MD, MPH, and Steven.
Principles of Clinical Chemistry Automation
Absolute and Relative Kinetic Changes of High-Sensitivity Cardiac Troponin T in Acute Coronary Syndrome and in Patients with Increased Troponin in the.
Panbio Dengue Duo Cassette
Verification of qualitative methods
Performance criteria or ”quality specifications” Gunnar Nordin Dubrovnik Course in Zagreb 2015.
Ischaemic Heart Disease CASE A. CASE A: Mr HA, aged 60 years, was brought in to A&E complaining of chest pain, nausea and a suspected AMI.
Verification of precision and bias
Implementation of a Sensitive Troponin I Assay and Risk of Recurrent Myocardial Infarction and Death in Patients With Suspected Acute Coronary Syndrome.
The percentage of values for cardiac troponin (cTn)T associated with elevated values for a point-of-care assay with less sensitivity and precision: the.
RESEARCH POSTER PRESENTATION DESIGN © Cardiac Troponin Assay Cardiac troponin I is the diagnostic marker used for myocardial.
Which troponin assay to choose? Clinical performances of troponin T and troponin I assays Per Venge, MD PhD Professor Department of Medical Sciences Uppsala.
Enzyme Linked Immunosorbent Assay
Troponin By Julie Moore C Dt204/2.
Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: Practical Management of Anticoagulation in Patients.
Date of download: 7/5/2016 Copyright © 2016 American Medical Association. All rights reserved. From: One-Hour Rule-out and Rule-in of Acute Myocardial.
Importance of the Clinical Laboratory 2014 Community Advocacy Committee.
Point of Care Testing - CLSI. Quality practices for better health. Our Vision Free Wind 2014 / Shutterstock.com.
1. Mini-Clinical Evaluation Exercise (mini-CEX) 2.
Incidence of Undetectable, Measurable, and Increased Cardiac Troponin I Concentrations Above the 99th Percentile Using a High-Sensitivity Versus a Contemporary.
Tobias Reichlin, M. D. , Willibald Hochholzer, M. D
Evaluating Sepsis Guidelines and Patient Outcomes
Contemporary Diagnosis and Management of Unstable Angina
Systolic Blood Pressure Intervention Trial (SPRINT)
Identifying Patients Suitable for Discharge After a Single-Presentation High-Sensitivity Troponin Result: A Comparison of Five Established Risk Scores.
AQT90 FLEX Radiometer Medical ApS
AQT90 FLEX – the product 28/11/2018.
Section A: Introduction
Advancing Acute Coronary Syndrome Assessment:
Built-in Hct & Software upgrade for AQT90 FLEX analyzer
Tuda G Kemri/Wellcome Trust Research Program
Kevin R. King et al. BTS 2016;1:73-86
Use of Neutrophil Count in Early Diagnosis and Risk Stratification of AMI  Julia Meissner, MD, Affan Irfan, MD, Raphael Twerenbold, MD, Sandra Mueller,
Clinical Policy: Critical Issues in the Evaluation and Management of Adult Patients with Non–ST-Segment Elevation Acute Coronary Syndromes  Francis M.
Pathfast Cardiac Biomarker Analyzer
Update on better disease diagnosis
 The use of 12 lead electrocardiography and cardiac troponins in the diagnostic evaluation of suspected acute coronary syndrome. *It is unusual to find.
Presentation transcript:

NOVELLO E., MION M.M., ZANINOTTO M., PLEBANI M. Department of Laboratory Medicine, University-Hospital, Padova (Italy). AQT90 FLEX is a fully automatic continuos-access analyzer, with a throughput up to 30 tests per hour. The analyzer performs sampling from a manually loaded capped primary sample tube, after which the automatic processing takes place; the measurement principle is a sandwich immunoassay based on universal all-in-one dry-reagent concept: the sample and the assay buffer are automatically added to the cup containing the assay-specific agents. The signal from the tracer antibody labeled with europium is measured by means of time- resolved fluorometry. Time to first result for cTnI is approximatively 18 minutes. cTnI values are expressed in µg/L. For the IMPRECISION STUDY, 9 plasma pools (PPs) (K2-EDTA) were tested for the intra-assay (n=10 for each PP) and beetween days (n=80 for each PP) imprecision respectively, according to CLSI (NCCLS) EP5-A protocol (Figure 1). For COMPARISON STUDY,108 matched whole blood (K2EDTA) and plasma (Lithium-heparin) samples were tested using the AQT90 FLEX and the RxL Dimension (Siemens Healthcare Diagnostic, USA), the analyzer used in our laboratory for the routine assays of cardiac markers (Figure 2 a,b). AQT90 FLEX cTnI concentrations were obtained at first, using a standard haematocrit proposed by manufacturer and subsequently, introducing a real hematocrit value obtained from routine analyzer (Sysmex XE-2100,Kobe, Japan). (Figure 3 a,b) Figure 1. Imprecision study Plasma pools concentrations for the between-day imprecision : µg/L Corresponding CV range : % Plasma pools concentrations for the intra-assay imprecision : µg/L Corresponding CV range : % 10% CV=0.023 µg/L. Figure 2 (a,b). AQT90 FLEX versus Dimension RxL Data from AQT90 FLEX were obtained using measured haematocrit cTnI concentration range: < µg/L. Applied cut-off: µg/L (AQT90 FLEX), 0.15 µg/L Dimension RxL). Linear regression analysis: AQT90 FLEX= X Dimension RxL (r=0.99) (a); Observed agreement: 98% (b) a) b) AQT 90 FLEX Dimension RxL AQT 90 FLEX Dimension RxL a) b) PositivecTnIN=82NegativecTnIN=26 PositivecTnIN=81 NegativecTnIN=27 PositivecTnIN=81 PositivecTnIN=81 NegativecTnIN=27 NegativecTnIN= Measurement of troponins plays a key role in the diagnosis of myocardial infarction and current guidelines (ESC/ACC) require that a tuornaround time (TAT) of 1 hour or less should be achieved for cardiac marker assay. On the other hand, the reorganization of Laboratory Medicine services in areas sometimes far away from Clinical Hospital, make these guidelines more difficult to support. The rationale for Point-Of-Care testing (POCT) Technology depends on the need and the ability to achieve a rapid TAT for decision making in the diagnosis of suspected Acute Coronary Syndrome. POCT can’t replace Laboratory tests, but must be accurate and equivalent to Laboratory based diagnosis. POCT has a definite setting in managment: when very short TAT is required, such as the Emergency Department, or whereas Laboratory Services are distant from Clinical Hospital. AIM OF THE STUDY was to evaluate analytical performances of the new POCT AQT90 FLEX analyzer (Radiometer Medical ApS Denmark) for cardiac troponin I (cTnI) determination. Standard hematocrit(42%) The cTnI measurement evaluated is a simple to use, rapid (time to first results: 18 min, continous samples loading) and safe POCT assay, showing satisfactory analytical performances. The technology is suitable for the measurements of cardiac troponin by unskilled personnel in critical settings such as in emergency department and cardiac care unit. Figure 3 (a,b). Hematocrit values in the population studied Measured hematocrit range: %. When comparing the AQT90 FLEX cTnI results obtained using the measured hematocrit and the standard hematocrit(42%), no differences in sample classification were evidenced.